Integrated Filing — IndAS



General information about company

Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 07-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-04-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 07-05-2026   13:45:00
End date and time of board meeting 07-05-2026   19:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 7,47,466.00 27,95,803.00
Other income 14,071.00 42,445.00
Total income 7,61,537.00 28,38,248.00
2 Expenses
(a) Cost of materials consumed 1,23,130.00 4,62,190.00
(b) Purchases of stock-in-trade 70,841.00 2,86,701.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (8,808.00) (16,245.00)
(d) Employee benefit expense 1,24,269.00 4,57,453.00
(e) Finance costs 12,016.00 43,449.00
(f) Depreciation, depletion and amortisation expense 44,679.00 1,37,550.00
(f) Other Expenses
1 Other Expenses (Refer note 7, 8 and 9) 2,20,927.00 7,89,751.00
2 Net (gain) / loss on Foreign Currency Transactions (31,451.00) (65,647.00)
Total other expenses 1,89,476.00 7,24,104.00
Total expenses 5,55,603.00 20,95,202.00
3 Total profit before exceptional items and tax 2,05,934.00 7,43,046.00
4 Exceptional items (13,134.00) (55,791.00)
5 Total profit before tax 1,92,800.00 6,87,255.00
6 Tax expense
7 Current tax 50,792.00 1,52,735.00
8 Deferred tax (4,859.00) (1,027.00)
9 Total tax expenses 45,933.00 1,51,708.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,46,867.00 5,35,547.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,46,867.00 5,35,547.00
17 Other comprehensive income net of taxes 6,426.00 44,040.00
18 Total Comprehensive Income for the period 1,53,293.00 5,79,587.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1,46,034.00 5,33,284.00
Total profit or loss, attributable to non-controlling interests 833.00 2,263.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 1,52,198.00 5,76,847.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 1,095.00 2,740.00
21 Details of equity share capital
Paid-up equity share capital 9,144.00 9,144.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 22,35,683.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 31.96 116.75
Diluted earnings (loss) per share from continuing operations 31.89 116.44
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 31.96 116.75
Diluted earnings (loss) per share from continuing and discontinued operations 31.89 116.44
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on May 07, 2026. 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. - Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquimica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A, Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A, Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India (formerly known as Lupin Atharv Ability Limited - India), Lupin Manufacturing Solutions Limited - India, Medisol S.A.S. - France, Lupin Lanka (Private) Ltd. - Sri Lanka (w.e.f. August 05, 2024), Lupin NZ Ltd. - New Zealand (w.e.f. August 08, 2024), Lupinlife Consumer Healthcare Limited - India (w.e.f. March 08, 2025), Renascience Pharma Limited - U.K. (w.e.f. April 02, 2025) and a joint venture, YL Biologics Limited - Japan. 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. 4. The Board of Directors have, at its meeting held on May 07, 2026 recommended a dividend of Rs. 18/- per equity share of the face value of Rs. 2/- each aggregating Rs. 8,229.2 million. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting. 5. During the quarter ended March 31, 2026, 380,305 (year to date 614,066) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up equity share capital by Rs. 0.7 million (year to date Rs. 1.2 million) and securities premium account by Rs. 463.2 million (year to date Rs. 719.7 million). 6. Exceptional items a. The Group is exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and possible violation of federal and state antitrust laws that are often resolved through settlement agreements. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended March 31, 2026 and December 31, 2025; the Group has based on best estimate, created a provision, of Rs. 1,323.1 million (USD 15.8 million) and of Rs. 4,493.8 million (USD 50 million) respectively, resulting in cumulative provision of Rs. 5,816.9 million (USD 65.8 million) at year ended March 31, 2026 related to antitrust litigation matters. In April 2026, LPI, a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matters for an amount of Rs. 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. The remaining provision continues to be carried by the Group towards future settlements related to similar cases. b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. In respect of the same, LPI paid Rs. 8,475.5 million (USD 90.0 million), which includes Rs. 7,110.8 million (USD 75.0 million) as Prepaid Option and Rs. 1,364.7 million (USD 15.0 million) as one-time payment towards the settlement. During the quarter ended December 31, 2025 and year ended March 31, 2026, the Group has expensed out Rs. 1,364.7 million (USD 15.0 million) and has capitalised the balance amount towards Prepaid Option. c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the New Labour Codes). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 512.2 million during the quarter ended December 31, 2025 and year ended March 31, 2026. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. d. During the quarter ended December 31, 2025 and year ended March 31, 2026, the Group entered into a settlement agreement with an income of Rs. 873.7 million (USD 10.0 million). e. During the quarter ended December 31, 2025 and year ended March 31, 2026, the Group has received an arbitration award, consequently accounted an income of Rs. 603.2 million (USD 6.9 million) and a reversal of expense provision of Rs. 611.6 million (USD 7.0 million). 7. During the year ended March 31, 2026, the Company through its wholly owned subsidiary Nanomi B.V., Netherlands (‘Nanomi’) has entered into a definitive agreement to acquire 100% share capital of VISUfarma B.V., Netherlands. The acquisition was concluded on April 01, 2026, with total consideration of Rs. 20,902.7 million (Euro 192.8 million). The acquisition related costs are accounted in Other expenses. 8. During the year ended March 31, 2026, the Company through its wholly owned step-down subsidiary, Lupin Healthcare (UK) Limited, U.K., acquired 100% equity share capital of Renascience Pharma Limited, U.K., for a consideration of Rs. 1,361.6 million (GBP 12.3 million). Fair value of intangibles acquired Rs. 1,239.4 million, deferred tax liability Rs. 309.8 million, Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. The acquisition related costs are accounted in Other expenses. 9. During the year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million (Rs. 750.5 million) in connection with the drug Glumetza� without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 10. During the quarter and year ended March 31, 2026 & quarter and year ended March 31, 2025, the Group has recognised an impairment charge of Rs. 879.1 milion and Rs. 1,130.1 milion & Rs. 1,135.3 milion and Rs. 1,209.0 milion respectively related to certain property, plant and equipment, capital work-in-progress, intangible assets, intangible assets under development and goodwill.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 5,44,910.00
Capital work-in-progress 69,516.00
Investment property 0.00
Goodwill 2,65,853.00
Other intangible assets 2,88,625.00
Intangible assets under development 32,095.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 2,898.00
Non-current financial assets
Non-current investments 6,356.00
Trade receivables, non-current 0.00
Loans, non-current 211.00
Other non-current financial assets
1 Other non-current financial assets 1,45,158.00
Total of other non-current financial assets 1,45,158.00
Total non-current financial assets 1,51,725.00
Deferred tax assets (net) 56,472.00
Other non-current assets
1 Non-Current Tax Assets (Net) 4,898.00
2 Other Non-Current Assets 16,753.00
Total of other non-current assets 21,651.00
Total non-current assets 14,33,745.00
2 Current assets
Inventories 6,08,325.00
Current financial asset
Current investments 3,57,713.00
Trade receivables, current 6,60,406.00
Cash and cash equivalents 4,16,773.00
Bank balance other than cash and cash equivalents 1,48,517.00
Loans, current 293.00
Other current financial assets
Total of other current financial assets 56,298.00
Total current financial assets 16,40,000.00
Current tax assets (net) 145.00
Other current assets
1 Other current assets 1,54,268.00
Total of other current assets 1,54,268.00
Total current assets 24,02,738.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 38,36,483.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,144.00
Other equity 22,35,683.00
Total equity attributable to owners of parent 22,44,827.00
Non controlling interest 6,510.00
Total equity 22,51,337.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,64,339.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 49,487.00
2 Other non-current financial liabilities 5,265.00
Total of other non-current financial liabilities 54,752.00
Total non-current financial liabilities 2,19,091.00
Provisions, non-current 53,270.00
Deferred tax liabilities (net) 21,877.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 25,784.00
Total of other non-current liabilities 25,784.00
Total non-current liabilities 3,20,022.00
Current liabilities
Current financial liabilities
Borrowings, current 4,26,681.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 15,731.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4,01,582.00
Total Trade payable 4,17,313.00
Other current financial liabilities
1 Lease Liabilities 21,111.00
2 Other current financial liabilities 1,12,202.00
Total of other current financial liabilities 1,33,313.00
Total current financial liabilities 9,77,307.00
Other current liabilities 1,64,889.00
1 Other current liabilities 1,64,889.00
Total of other current liabilities 1,64,889.00
Provisions, current 56,124.00
Current tax liabilities (Net) 66,804.00
Deferred government grants, Current
Total current liabilities 12,65,124.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 15,85,146.00
Total equity and liabilites 38,36,483.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 7,43,474.00 27,81,236.00
2 Others 4,047.00 14,739.00
3 Less: Inter segment Assets 0.00 0.00
4 Less: Inter segment Liabilities 0.00 0.00
Total Segment Revenue 7,47,521.00 27,95,975.00
Less: Inter segment revenue 55.00 172.00
Revenue from operations 7,47,466.00 27,95,803.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 1,97,710.00 7,05,027.00
2 Others (4,910.00) (17,772.00)
3 Less: Inter segment Assets 0.00 0.00
4 Less: Inter segment Liabilities 0.00 0.00
Total Profit before tax 1,92,800.00 6,87,255.00
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax 1,92,800.00 6,87,255.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 38,12,860.00 38,12,860.00
2 Others 23,946.00 23,946.00
3 Less: Inter segment Assets (323.00) (323.00)
4 Less: Inter segment Liabilities 0.00 0.00
Total Segment Asset 38,36,483.00 38,36,483.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 38,36,483.00 38,36,483.00
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 15,74,622.00 15,74,622.00
2 Others 10,847.00 10,847.00
3 Less: Inter segment Assets 0.00 0.00
4 Less: Inter segment Liabilities (323.00) (323.00)
Total Segment Liabilities 15,85,146.00 15,85,146.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 15,85,146.00 15,85,146.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be re-classified to profit or loss 52.00 (639.00)
Total Amount of items that will not be reclassified to profit and loss 52.00 (639.00)
2 Income tax relating to items that will not be reclassified to profit or loss 193.00 (11.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 5,176.00 41,956.00
Total Amount of items that will be reclassified to profit and loss 5,176.00 41,956.00
4 Income tax relating to items that will be reclassified to profit or loss (1,391.00) (2,712.00)
5 Total Other comprehensive income 6,426.00 44,040.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 6,87,255.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 43,449.00
Adjustments for decrease (increase) in inventories (58,590.00)
Adjustments for decrease (increase) in trade receivables, current (73,875.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (28,551.00)
Adjustments for decrease (increase) in other non-current assets 1,467.00
Adjustments for other financial assets, non-current 531.00
Adjustments for other financial assets, current (22,342.00)
Adjustments for other bank balances 21,113.00
Adjustments for increase (decrease) in trade payables, current 1,19,056.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 50,529.00
Adjustments for increase (decrease) in other non-current liabilities 5,279.00
Adjustments for depreciation and amortisation expense 1,37,550.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 28,688.00
Adjustments for provisions, non-current 4,917.00
Adjustments for other financial liabilities, current 36,170.00
Adjustments for other financial liabilities, non-current 90.00
Adjustments for unrealised foreign exchange losses gains (41,012.00)
Adjustments for dividend income 0.00
Adjustments for interest income 21,861.00
Adjustments for share-based payments 3,895.00
Adjustments for fair value losses (gains) (5,928.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (12,923.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 6,391.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,94,043.00
Net cash flows from (used in) operations 8,81,298.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,26,735.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 7,54,563.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 3,069.00
Cash flows used in obtaining control of subsidiaries or other businesses 13,575.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 24,770.00
Purchase of property, plant and equipment 2,05,485.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 21,687.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (2,38,038.00)
Net cash flows from (used in) investing activities (4,07,572.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1,646.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 27,904.00
Repayments of borrowings 0.00
Payments of lease liabilities 16,449.00
Dividends paid 54,834.00
Interest paid 36,147.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (6,707.00)
Net cash flows from (used in) financing activities (84,587.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 2,62,404.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 2,62,404.00
Cash and cash equivalents cash flow statement at beginning of period 1,54,369.00
Cash and cash equivalents cash flow statement at end of period 4,16,773.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-07-2028